Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

Biopharmaceutical research company pursues faster route for drug discovery using PhAROS, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships

LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up the process and is developing key relationships to further advance the clinical development of its novel, plant-inspired therapies for the prescription drug market.

To expedite its discovery processes, Gb Sciences utilizes its revolutionary drug discovery platform called PhAROS. PhAROS, short for Phytomedical Analytics for Research Optimization at Scale, predicts novel formulations of therapeutic mixtures derived from plant-based materials. PhAROS combines the wisdom of traditional plant-based medicines with the speed of modern data analytics and machine learning, which allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market.

"Our research and development processes are very innovative because we know that the development of novel drugs through traditional biopharmaceutical pipelines is very slow," says Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. "It typically takes at least 10 years for a new medicine to go from the initial discovery phase to the marketplace, and during that time, millions are left hoping and waiting for symptom relief."

Gb Sciences' novel approach to drug discovery increases research efficiency and reduces Gb Sciences' time from ideation to drug candidate selection from seven years to 1.5 years. Gb Sciences combines both its PhAROS drug discovery platform for the identification and prediction of the efficacy of plant-derived, therapeutic mixtures for specific diseases in silico, and then Gb Sciences tests these minimum essential mixtures from plants using robotics-aided screening of plant mixtures in cell and animal models of specific diseases. Using both its drug discovery platform and high throughput screening systems, the company has identified and validated precise mixtures of plant-based compounds to treat conditions including neurological disorders, inflammation, anxiety, depression, heart disease, metabolic syndrome, and chronic pain.